Joseph Stringer
Stock Analyst at Needham
(4.14)
# 206
Out of 5,182 analysts
304
Total ratings
47.9%
Success rate
13.71%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Hold | n/a | $40.41 | - | 22 | Mar 31, 2026 | |
| BIOA BioAge Labs | Initiates: Buy | $50 | $17.50 | +185.71% | 1 | Mar 27, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $103 → $105 | $74.79 | +40.39% | 27 | Mar 25, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $35 → $40 | $32.74 | +22.17% | 25 | Mar 17, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $139 → $130 | $86.29 | +50.65% | 31 | Mar 17, 2026 | |
| VIR Vir Biotechnology | Maintains: Buy | $14 → $18 | $9.06 | +98.68% | 20 | Feb 24, 2026 | |
| GILD Gilead Sciences | Reiterates: Buy | $170 | $139.71 | +21.68% | 11 | Feb 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $510 | $318.85 | +59.95% | 25 | Feb 12, 2026 | |
| PCVX Vaxcyte | Maintains: Buy | $90 → $110 | $58.38 | +88.42% | 18 | Jan 7, 2026 | |
| MRNA Moderna | Reiterates: Hold | n/a | $49.20 | - | 9 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 | $11.34 | +146.91% | 52 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $5.50 | +100.00% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $438.71 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.59 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.35 | +640.74% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $22.20 | +66.70% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $16.02 | +12.36% | 2 | Aug 24, 2021 |
Apellis Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: n/a
Current: $40.41
Upside: -
BioAge Labs
Mar 27, 2026
Initiates: Buy
Price Target: $50
Current: $17.50
Upside: +185.71%
Ionis Pharmaceuticals
Mar 25, 2026
Maintains: Buy
Price Target: $103 → $105
Current: $74.79
Upside: +40.39%
Stoke Therapeutics
Mar 17, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $32.74
Upside: +22.17%
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Buy
Price Target: $139 → $130
Current: $86.29
Upside: +50.65%
Vir Biotechnology
Feb 24, 2026
Maintains: Buy
Price Target: $14 → $18
Current: $9.06
Upside: +98.68%
Gilead Sciences
Feb 23, 2026
Reiterates: Buy
Price Target: $170
Current: $139.71
Upside: +21.68%
Alnylam Pharmaceuticals
Feb 12, 2026
Maintains: Buy
Price Target: $529 → $510
Current: $318.85
Upside: +59.95%
Vaxcyte
Jan 7, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $58.38
Upside: +88.42%
Moderna
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $49.20
Upside: -
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $11.34
Upside: +146.91%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $5.50
Upside: +100.00%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $438.71
Upside: -
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.59
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.35
Upside: +640.74%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $22.20
Upside: +66.70%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $16.02
Upside: +12.36%